Skip to main content

Table 1 Patients’ characteristics

From: Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

 

N pts

%

Gender

  Female

11

44

  Male

14

56

Age

  <60

13

52

  > r =60

12

48

ECOG

  0

9

36

  1

15

60

  2

1

4

Tobacco

  Current smoker

4

16

  Never smoker

7

28

  Former smoker

14

56

Histology

  Adenocarcinoma

22

88

  Adenocarcinoma poorly differentiated

2

8

  Adeno-squamous

1

4

T

  T1-2

12

48

  T3-4

13

52

N

  N0

6

24

  N+

19

76

M

  M0

7

28

  M1

18

72

Lung metastases

  Presence

7

28

  Absence

18

72

Liver metastases

  Presence

2

8

  Absence

23

92

Bone metastases

  Presence

10

40

  Absence

15

60

Brain metastases

  Presence

8

32

  Absence

17

68

EGFR

  Wild type

23

92

  Mutant

1

4

  Unknown

1

4

Line of treatment

  First/Induction (stage III)

2

8

  First

21

84

  Second

1

4

  Third

1

4

Response

  Response

18

72

  Progression + Stabilization

7

28

Maintenance

  No maintenance

18

72

  Maintenance

7

28

Progression

  Not progressed

6

24

  Progressed

19

76

Clinical status

  Alive

12

48

  Dead

13

52

  1. Eastern Cooperative Oncology Group (ECOG). Epidermal Growth Factor Receptor (EGFR).